CSC Strengthens Leadership in Funds and Capital Markets Division with Two Key Appointments
CSC, the world’s leading provider of global business administration and compliance solutions, is pleased to announce the expansion of its newly combined Funds and Capital Markets (FCM) division, with the strategic appointments of John Hebert and Venkat Srinivasan.
The move follows CSC’s announcement earlier this year that the Intertrust Group acquisition of November 2022 had been fully integrated and migrated to the CSC brand. CSC delivers unmatched client service, market-leading expertise, and global solutions consistently, through more than 8,000 dedicated employees, and with capabilities across more than 140 jurisdictions.
By combining CSC’s existing Funds and Capital Markets businesses, which span five continents and a team of several thousand experts, the integration and new leadership will facilitate accelerated growth plans and enable a comprehensive and tailored service offering for fund managers, asset owners, lenders, and their advisors.
As part of the ambitious new plans for FCM, John Hebert will extend his leadership role to incorporate Funds, moving from executive vice president and president of Global Capital Markets (GCM) to become the executive vice president and president of the FCM division. In this role, he will provide overall direction and leadership for CSC’s global offering, looking at how CSC’s comprehensive suite of products and innovations can be tailored to support clients across multiple asset classes, structures, and geographies. In his previous role, Hebert served as president of CSC’s Global Financial Markets business, overseeing a period of global expansion and dramatic growth that resulted in a 250% increase in capital markets and funds revenue over five years. He started his CSC career by co-leading the firm’s corporate development activities, where he successfully closed several acquisitions. Prior to joining CSC, Hebert held senior roles in asset management and investment banking.
Venkat Srinivasan has been appointed global head of funds and enterprise capabilities where he will lead the service, operations, and technology development of CSC’s funds business and deliver enhanced, centralized solutions that address the evolving needs of the funds industry. Srinivasan was formerly co-head of the funds business at Intertrust Group, focusing on private equity. He has more than 25 years of experience in financial services, nearly two decades of which have been dedicated to funds.
Rod Ward, president and CEO, CSC commented, “We are excited to welcome John and Venkat into their new roles as we continue to drive growth across our core markets. They have already demonstrated exceptional leadership capabilities at CSC, and together will be invaluable in setting the strategic direction for our FCM business. As we streamline and expand the suite of FCM services we have in place to support our clients’ increasingly complex needs, we do so with a focus on the long term. This year, CSC celebrated 125 years of business under common ownership, and that success is driven by our people-focused culture. Both John and Venkat foster that culture while embedding a growth mindset and entrepreneurial spirit. I am excited about the opportunities ahead and confident that John and Venkat’s contributions will drive significant value for our clients.”
About CSC
CSC is the trusted partner of choice for more than 90% of the Fortune 500®, more than 90% of the 100 Best Global Brands (Interbrand®), and more than 70% of the PEI 300. We are the world’s leading provider of global business administration and compliance solutions, specialized administration services to alternative asset managers across a range of fund strategies, transactions involving capital markets participants in both public and private markets, domain name system management and digital brand and fraud protection, and corporate tax software solutions. Founded in 1899 and headquartered in Wilmington, Delaware, USA, CSC prides itself on being privately held and professionally managed for more than 125 years. CSC has office locations and capabilities in more than 140 jurisdictions across Europe, the Americas, Asia Pacific, and the Middle East. We are a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. We are the business behind business®. Learn more at cscglobal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241216527189/en/
Contacts
For more information:
Citigate Dewe Rogerson
Thomas Dalton
cscteam@citigatedewerogerson.com
CSC
Laura Crozier
PR Manager
laura.crozier@cscglobal.com
CSC® Newsroom -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cscglobal.
com%2Fservice%2Fpress%2F&esheet=54166660&newsitemid=20241216527189&lan=en-US&anc
hor=CSC%26%23174%3B+Newsroom&index=2&md5=ccb06c74b190cc421416f7d7081e47d1
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 23:30:00 EEST | Press release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 23:05:00 EEST | Press release
IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 22:26:00 EEST | Press release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 22:24:00 EEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 22:08:00 EEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom